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Summary
Persisting symptoms and dysfunction after SARS-CoV-2 infection
have frequently been observed. However, information on the
aftermath of COVID-19 is inadequate. We followed up people
with severe mental illness (SMI) infected with SARS-CoV-2, and
evaluated their longer-term mortality, using data from
Cambridgeshire and Peterborough NHS Foundation Trust, UK.
We examined the time course and duration of mortality risk from
the point of diagnosis. After SARS-CoV-2 infection, people with
SMI had a substantially higher risk of death (hazard ratio (HR) =
5.16, 95% confidence interval (CI) 1.56–17.03; P = 0.007) during
the first 28 days and during the following 28–60 days (HR = 2.96,
95% CI 1.21–7.26; P = 0.018) than those without infection, but
after 60 days the additional risk of deathwas no longer significant
(HR = 2.33, 95% CI 0.83–6.53; P = 0.107).
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People with severe mental illness (SMI) are at increased risk of being
infected by SARS-CoV-2 and have increased mortality and a more
severe course of COVID-19.1–5 In the UK and other countries, the
attribution of death to COVID-19 is restricted to the first 28 days
after a positive COVID-19 test.6 Peak mortality is estimated to be
9–16 days after diagnosis.7,8 However, 45-day mortality in SMI is
elevated after COVID-19 infection.2 The full time course and dur-
ation of elevated mortality risk following COVID-19 infection in
SMI is therefore unclear, and one possibility is that the mortality
risk extends beyond 28 days. In this study, we conducted a
longer-term follow-up of this group of patients and explored their
longer-term mortality. We hypothesised that the mortality caused
by SARS-CoV-2 infection beyond 28 days is still significant.
Method
Study design and participants
We conducted a retrospective case-matched study using data from
the mental health electronic clinical records of Cambridgeshire and
Peterborough NHS Foundation Trust (CPFT) in the UK. CPFT
covers a population of approximately 0.86 million people and pro-
vides secondary mental health and community physical health ser-
vices. Data from CPFT include sociodemographic information,
diagnosis, smoking status and death status. Clinicians enter this infor-
mation during patients’ routine treatment in a systematic and stand-
ard way to ensure its accuracy.9 SARS-CoV-2 status was confirmed by
the reverse transcription polymerase chain reaction (RT-PCR) test
recommended by the World Health Organization (WHO).
Data were collected from 1 March 2020 to 28 February 2021, to
avoid the influence of the SARS-CoV-2 vaccination widely available
from March 2021 in the UK. Eligible patients were those diagnosed
with SMI. SMI was judged on the basis of the ICD-10 diagnosis
codes F20–F29 (including schizophrenia, delusional disorders and
schizotypal disorder), F30 (manic episode) and F31 (bipolar affect-
ive disorder). The exposure cohort were people with SMI who had
laboratory-confirmed SARS-CoV-2. The control group were
matched (at a ratio of 1:10) from the remaining people with SMI,
matched on age (±1 year) and gender. The origin time was the
date of COVID-19 diagnosis (exposure cohort) or the matched
exposed case’s date of COVID-19 diagnosis (control cohort).
Follow-up was until the study end date, the patient’s final recorded
CPFT data or the date of their death, whichever occurred first.
Data collection
The following sociodemographic variables were extracted: age at base-
line (years), gender (female versus male), marital status (married, civil
partnership or cohabiting versus not) and ethnicity (White versus
other/not known). Smoking status was defined as being a past or
current smoker. Death status for all patients known to the CPFT was
extracted by weekly linkage to the national NHS Spine mortality data.
We selected comorbidities that were plausible risk factors for a
worse prognosis2,10 as follows: myocardial infarction (ICD-10
codes I21–I25), hypertension (ICD-10 H35.03, I10–I16, I67.4,
O10.1–O10.4 and O10.9), heart failure (ICD-10 I11.0, I13.0, I13.2,
I42 and I50), diabetes mellitus (ICD-10 E08–E13), chronic kidney
disease (ICD-10 D63.1, E08.22, E10.22, E11.22, E13.22, I12, I13,
N03, N18, O10.3, Z49, Z91.15 and Z99.2), obstructive lung
disease (ICD-10 J40–J47, J60, J66, J67.2, J67.8, J67.9, J68.4, J84
and G47.3) and cancer (ICD-10 C00–D49).
Statistical analysis
Continuous variables were reported as mean (s.d.) and categorical
variables were reported as n (%). Differences between groups were
tested via two-tailed t-tests (for continuous variables) and chi-
squared tests (for categorical variables).
The Cox proportional hazard model was used to estimate the
association between SARS-CoV-2 infection and mortality, controlling
for sociodemographic variables and comorbidities, with matching
group identity as a cluster variable. We first plotted the hazard ratio
(HR) against follow-up time from the overall Cox regression, extracted
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from Schoenfeld residuals, a method originally used for graphically
testing the proportional hazards assumption. We then conducted pie-
cewise Cox regression to estimate the effect of SARS-CoV-2 infection
onmortality during different follow-up periods.We chose 28 days and
60 days as the follow-up thresholds: 28 days is the limit of COVID-
attributable death according to the National Health Service (NHS)6
and 60 days was derived from the plot (Fig. 1(a)).
All analyses were done in R (v3.5.0) on Windows. P < 0.05 was
treated as statistical significance. We report results following the
STROBE checklist.
Ethics statement
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and institu-
tional committees on human experimentation and with the Helsinki
Declaration of 1975, as revised in 2008. All procedures involving
human participants/patients were approved by an NHS Research
Ethics committee (reference 17/EE/0442). Individual patient consent
was not necessary as data were extracted from de-identified electronic
clinical records; no patients were involved in the development of the
research question or the outcome measures, or in developing plans
for the design and analysis of the study.
Results
Between 1March 2020 and 28 February 2021, a total of 121 individuals
with SMIand infectedwith SARS-CoV-2were included in the exposure
cohort, and 1210 individuals with SMI without SARS-CoV-2 infection
were matched from 22 048 individuals with SMI and included in the
control cohort (supplementary material available at https://doi.org/10.
1192/bjo.2021.1046). The SARS-CoV-2 exposure cohort was followed
up for an average of 159 days (s.d. = 123.6), significantly lower than that
in the control cohort (186 days (s.d. = 120.1); P = 0.025). Some differ-
ences in baseline characteristics were identified between the two
cohorts (see supplementary material). Individuals in the SARS-
CoV-2 cohort were more likely to be of ‘other/not known’ ethnicity
(P = 0.003), to be former/current smokers (P = 0.001), and to have
comorbid hypertension (P = 0.004), diabetes mellitus (P = 0.016),
chronic kidney disease (P < 0.001) or cancer (P = 0.029). No significant
difference was observed between the two cohorts for other characteris-
tics, including age, gender, marital status, heart failure, myocardial
infarction or obstructive lung disease. Sixteen deaths (13.2%, or 303.6
per 1000personsper year)were identified in the SARS-CoV-2 exposure
cohort, a significantly higher fraction (P < 0.001) than in the unexposed
cohort (33 deaths, 2.7%, or 53.5 per 1000 persons per year).
The Schoenfeld residuals from the overall Cox regression sug-
gested that the effect of SARS-CoV-2 infection on mortality dimin-
ished from the start of the follow-up and disappeared from
approximately 60 days until the end of the follow-
up period (Fig. 1(a)). The piecewise regression indicated that indi-
viduals with SMI exposed to SARS-CoV-2 had a 4.16-fold higher
risk of death (HR = 5.16, 95% CI 1.56–17.03; P = 0.007) during
the first 28 days, and this additional death risk reduced to 1.96-
fold but was still significant (HR = 2.96, 95% CI 1.21–7.26; P =
0.018) during the period of 28–60 follow-up days. After 60 days the
additional risk of death following SARS-CoV-2 infection was not
significant (HR = 2.33, 95% CI 0.83–6.54; P = 0.107) (Fig. 1(b)).
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Fig. 1 Association between SARS-CoV-2 infection and mortality, controlling for sociodemographic variables and comorbidities, with matching
group identity as the cluster variable. (a) Hazard ratio (with 95% confidence interval (CI)) against follow-up time: the solid line is a natural spline fit
(with 4 degrees of freedom as recommended15) of the time-varying estimates of the hazard ratio, with the shaded area representing a ±1.96
standard error band around the fit. (b) Piecewise results of the association between SARS-CoV-2 infection and mortality.
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Results remained consistent after removing one patient with
myocardial infarction and three patients with cancer.
Discussion
These findings supported our hypothesis that the additional mortal-
ity following SARS-CoV-2 infection persists beyond 28 days,
although it decreases over time, and also indicated that this increased
risk formortality was no longer statistically significant about 60 days
after infection. Our results before the 28-day point are in line with
previous studies, which concluded that people with SMI have an
increased risk for COVID-19-associated mortality.1,2,4,5,10,11 Our
study has quantified the dynamic change of this association and
reports on the aftermath of COVID-19 in people with SMI in a
longer follow-up period. Our results have implications for clinical
practice and suggest that people with SMI who are infected with
SARS-CoV-2 should have follow-up observations for at least 60
days even if they have recovered or been discharged. Our findings
also suggest that the 28-day cut-off adopted by theUK6might under-
estimate COVID-19-associated mortality in this population.
To the best of our knowledge, this is the first study to examine
mortality in people with SMI following COVID-19 infection using
uninfected peoplewith SMI as a comparison group. This is a strength
of our study, as people with SMI are at increased risk of premature
mortality due to a variety of causes. The crude death rate in our
control group is 53.5 per 1000 persons per year, higher than that
reported in general populations (10.4 per 1000 persons per year in
2020).12,13 This study design provides a more accurate assessment
of excessmortality related toCOVID-19 infection in this population.
The current work has several limitations. First, our data did not
contain information on the severity of symptoms for individuals
infectedwith SARS-CoV-2. The long-termhealth sequelae are particu-
larly relevant to those who required mechanical ventilation, for whom
long-term complications and incomplete recovery would more likely
be expected.1,14 Second, the sample is small, which prevented us
from performing subgroup analyses for different types of SMI.
Third, the control cohort may have included people with undiagnosed
COVID-19 infection. Fourth, the use of secondary care datamay have
led to unmeasured biases (versus peoplewith SMInot under the care of
secondarymental health services). Fifth, the retrospective study design
did not allow collection of data on persistent symptoms/disability
among survivors of SARS-CoV-2 infection. Prospective studies in
this area are required, considering also the specific cause of death.
Similar studies in the general population are also needed, as a pro-
longed mortality risk may be a more widespread phenomenon.
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